Oct 27, 2016
Mateon Expands Board of Directors with the Appointments of Donald R. Reynolds and Bobby W. Sandage, Jr., Ph.D.
Oct 10, 2016
Mateon Announces Issuance of US Patent for Cathepsin Inhibition
Sep 26, 2016
Mateon Announces Collaboration with US Oncology Research to Participate in Phase 2/3 FOCUS Study
Sep 20, 2016
Mateon Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016
Sep 07, 2016
Mateon Therapeutics to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York on September 12, 2016
Aug 03, 2016
Mateon Provides Corporate Update and Reports Second Quarter 2016 Financial Results
Jul 21, 2016
Mateon Announces Enrollment of First Patient in Phase 2 Portion of PAZOFOS Study in Recurrent Ovarian Cancer
Jun 23, 2016
Mateon Announces Initiation of FOCUS Study in Platinum-Resistant Ovarian Cancer
Jun 20, 2016
UPDATE -- Mateon Therapeutics to Present New Improved Survival Outcomes for CA4P in Recurrent Ovarian Cancer at June 27 Investor Event
Jun 20, 2016
Mateon Therapeutics to Present New Improved Survival Outcomes for CA4P in Recurrent Ovarian Cancer at June 27 Investor Event
12
13
14
15
16
17
<<
<
>
>>
Copyright © 2021 Oncotelic Inc., a TGF ImmunoOncology Company. All rights reserved.
Privacy